CD137-CRDI is not necessary in the role of contacting its natural ligand.
Immunol Cell Biol
; 95(1): 24-32, 2017 01.
Article
em En
| MEDLINE
| ID: mdl-27430526
ABSTRACT
Immune checkpoint inhibitors result in impressive clinical responses and are expanding to treat a wide variety of tumors. One common problem is low responses from current clinical trials that only benefit a fraction of patients. One key promising direction is combination therapy to increase clinical benefit. CD137, a well-defined antitumor target, can cause strong co-stimulating activity and break immune tolerance. In this study, the role of CD137-CRDI (cysteine rich domain I) in the binding of CD137-CD137L was further investigated based on our previous work. The results revealed that CRDI-mediated limited CD137 assembly without relying on CD137L. Furthermore, CRDI was not involved in direct contact with CD137L in either mice or humans. Isolated mouse CRDII and human CRDII+CRDIII were proven to be the minimum unit for interface with their respective ligands. Fine-tuning of this signaling may improve CD137-targeting strategy.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Ligante 4-1BB
/
Membro 9 da Superfamília de Receptores de Fatores de Necrose Tumoral
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article